Phil Johnson

Company: Interius Bio

Job title: Chief Scientific Officer

Seminars:

In Vivo Generation of CAR-T & NK cells Using an Engineered Lentiviral Vector 4:00 pm

• Specific targeting of CD7 cells in vivo creates CAR-T and NK cells • CD20 targeted for B-cell malignancies • CD19 targeted for autoimmune applications • Clinical entry Q424 for CD20 programRead more

day: Day Two, Non-Tracked PM